Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

@article{Khatri2011ComparisonOF,
  title={Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.},
  author={Bhupendra O Khatri and Frederik Barkhof and Giancarlo Comi and H C Hartung and Ludwig Kappos and Xavier Montalban and Jean Pelletier and Tracy Stites and Stacy S Wu and Fred K Holdbrook and Lixin Zhang-Auberson and Gordon Francis and Jeffrey A. Cohen},
  journal={The Lancet. Neurology},
  year={2011},
  volume={10 6},
  pages={520-9}
}
BACKGROUND In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORMS, fingolimod showed greater efficacy on relapse rates and MRI outcomes compared with interferon beta-1a. We had two aims in our extension: to compare year 2 with year 1 in the switched patients to assess the effect of a change from interferon beta-1a to fingolimod, and to compare over 24 months the treatment groups as originally randomised to assess the effect of delaying the start… CONTINUE READING